EnteroMedics

EnteroMedics, founded in 2002 and based in St. Paul, Minnesota, was a medical device company dedicated to developing minimally invasive technologies for treating obesity and related metabolic diseases. The company specialized in neuroblocking technology, particularly through its flagship product, the vBloc® Neurometabolic Therapy. This therapy utilized a pacemaker-like device, the vBloc® System, to intermittently block hunger signals on the vagus nerve, helping patients manage their appetite and reduce food intake. In 2017, EnteroMedics expanded its offerings by acquiring ReShape Medical, which developed the ReShape Dual Weight Loss Balloon®, an FDA-approved intragastric balloon system. The company also acquired BarioSurg, gaining the investigational Gastric Vest System™. Following these acquisitions, EnteroMedics rebranded as ReShape Lifesciences Inc. to reflect its broader focus on providing innovative solutions for obesity and associated health conditions. The company aimed to support patients in achieving healthier lives through its range of minimally invasive treatment options.

• Employees 15
• Founded 2002
• Total Funding $120101349